Syndax Pharmaceuticals, Inc. (SNDX)
Stock Price:
$16.01 USD
0.87 (5.75%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
617.17M |
| Revenue (ttm) |
1.52M |
| Net Income (ttm) |
-59.13M |
| Shares Out |
38.55M |
| EPS (ttm) |
-1.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$16.01 |
| Previous Close |
$15.14 |
| Change ($) |
0.87 |
| Change (%) |
5.75% |
| Day's Open |
15.24 |
| Day's Range |
15.12 - 16.18 |
| Day's Volume |
590,192 |
| 52-Week Range |
5.35 - 21.97 |
More Stats
| Market Cap |
617.17M |
| Enterprise Value |
450.87M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.55M |
| Float |
29.41M |
| EPS (basic) |
-1.83 |
| EPS (diluted) |
-1.82 |
| FCF / Share |
-1.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.49M |
| Short Ratio |
12.87 |
| Short % of Float |
15.28% |
| Beta |
1.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
407.11 |
| PB Ratio |
3.95 |
| Revenue |
1.52M |
| Operating Income |
-59.06M |
| Net Income |
-59.13M |
| Free Cash Flow |
-58.59M |
| Net Cash |
166.31M |
| Net Cash / Share |
4.31 |
| Gross Margin |
100.00% |
| Operating Margin |
-3,896.04% |
| Profit Margin |
-3,900.20% |
| FCF Margin |
-3,864.64% |
| ROA |
-26.37% |
| ROE |
-58.28% |
| ROIC |
-92.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$23.00*
(43.66% upside)
Low
16.0
Current: $16.01
High
27.0
Target: 23.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 1.52 | 1.52 | 2.11 | 1.22 | 0.63 | - |
| Revenue Growth | 0% | -28.04% | 72.79% | 94.58% | - | - |
| Gross Profit | 1.52 | 1.52 | 2.11 | 1.22 | 0.63 | - |
| Operating Income | -57.54 | -75.88 | -61.95 | -43.77 | -20.51 | -21.33 |
| Net Income | -56.05 | -73.96 | -60.80 | -47.07 | -104 | -26.36 |
| Shares Outstanding | 30.49 | 25.37 | 21.00 | 14.62 | 0.07 | 0.06 |
| Earnings Per Share | -1.84 | -2.92 | -2.90 | -3.22 | -1,519.27 | -453.02 |
| Operating Cash Flow | -50.61 | -68.53 | -47.37 | -35.16 | -2.43 | -14.39 |
| Capital Expenditures | - | -0.19 | -0.08 | -0.26 | -0.05 | - |
| Free Cash Flow | -50.61 | -68.72 | -47.46 | -35.42 | -2.48 | -14.40 |
| Cash & Equivalents | 59.78 | 81.01 | 130 | 105 | 86.54 | 12.26 |
| Total Debt | 0.90 | - | - | - | - | 13.88 |
| Net Cash / Debt | 58.88 | 81.01 | 130 | 105 | 86.54 | -1.63 |
| Assets | 63.53 | 83.94 | 137 | 109 | 89.90 | 12.82 |
| Liabilities | 31.93 | 30.89 | 32.87 | 24.87 | 23.21 | 18.53 |
| Book Value | 31.60 | 53.05 | 104 | 84.14 | -252 | -153 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Syndax Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
35 |
| CEO |
Briggs W. Morrison |
Stock Information
| Ticker Symbol |
SNDX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SNDX |
| IPO Date |
March 3, 2016 |
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Company The company was founded in 2005 and is headquartered in Waltham, Massachusetts.